These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19303620)

  • 1. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
    Pugach P; Ray N; Klasse PJ; Ketas TJ; Michael E; Doms RW; Lee B; Moore JP
    Virology; 2009 May; 387(2):296-302. PubMed ID: 19303620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
    Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
    J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
    Pugach P; Marozsan AJ; Ketas TJ; Landes EL; Moore JP; Kuhmann SE
    Virology; 2007 Apr; 361(1):212-28. PubMed ID: 17166540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
    Anastassopoulou CG; Ketas TJ; Klasse PJ; Moore JP
    Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5318-23. PubMed ID: 19289833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
    Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
    Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
    J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
    Anastassopoulou CG; Ketas TJ; Sanders RW; Klasse PJ; Moore JP
    Virology; 2012 Jul; 428(2):86-97. PubMed ID: 22520838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
    Berro R; Klasse PJ; Jakobsen MR; Gorry PR; Moore JP; Sanders RW
    Virology; 2012 Jun; 427(2):158-65. PubMed ID: 22424737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
    Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
    J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
    Wu E; Du Y; Gao X; Zhang J; Martin J; Mitreva M; Ratner L
    J Virol; 2019 May; 93(9):. PubMed ID: 30787151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
    Pfaff JM; Wilen CB; Harrison JE; Demarest JF; Lee B; Doms RW; Tilton JC
    J Virol; 2010 Jul; 84(13):6505-14. PubMed ID: 20410277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.
    Pugach P; Ketas TJ; Michael E; Moore JP
    Virology; 2008 Aug; 377(2):401-7. PubMed ID: 18519143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
    Tsibris AM; Korber B; Arnaout R; Russ C; Lo CC; Leitner T; Gaschen B; Theiler J; Paredes R; Su Z; Hughes MD; Gulick RM; Greaves W; Coakley E; Flexner C; Nusbaum C; Kuritzkes DR
    PLoS One; 2009 May; 4(5):e5683. PubMed ID: 19479085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
    Heredia A; Latinovic O; Gallo RC; Melikyan G; Reitz M; Le N; Redfield RR
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20476-81. PubMed ID: 19075241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.